88796-11-6

Upstream product

• 301665-60-1 1-benzyl-4-bromopiperidine 
• 100-47-0 benzonitrile 
• 10315-07-8 N-benzylpiperidine-4-carboxylic acid 
• 100-59-4 phenylmagnesium chloride 
• 62718-31-4 1-benzylpiperidine-4-carbonitrile 
• 2116-65-6 4-benzyl pyridine 
• 94913-90-3 (1-benzyl-[4]piperidyl)-phenyl-methanol; hydrochloride 

Downstream Products

• 725273-05-2 C-(1-benzyl-piperidin-4-yl)-C-phenyl-methylamine 

Relevant academic research and scientific papers

GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes

GPR52 is an orphan G protein-coupled receptor (GPCR) that has been recently implicated as a potential drug target of Huntington's disease (HD), an incurable monogenic neurodegenerative disorder. In this research, we found that striatal knockdown of GPR52 reduces mHTT levels in adult HdhQ140 mice, validating GPR52 as an HD target. In addition, we discovered a highly potent and specific GPR52 antagonist Comp-43 with an IC50 value of 0.63 μM by a structure-activity relationship (SAR) study. Further studies showed that Comp-43 reduces mHTT levels by targeting GPR52 and promotes survival of mouse primary striatal neurons. Moreover, in vivo study showed that Comp-43 not only reduces mHTT levels but also rescues HD-related phenotypes in HdhQ140 mice. Taken together, our study confirms that inhibition of GPR52 is a promising strategy for HD therapy, and the GPR52 antagonist Comp-43 might serve as a lead compound for further investigation.

1,4-DlSUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS

The use of a compound of formula (I) in the manufacture of a medicament for use in the inhibition of 11 betaHSD1 is described.

SUBSTITUTED 3- AND 4- AMINOMETHYLPIPERIDINES FOR USE AS BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER’S DISEASE

The invention relates to novel compounds, which are substituted chiral or achiral derivatives of 3- or 4- aminomethylpiperidine of the general formula (I). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula (I) and especially their use as inhibitors of beta-secretases for the treatment of Alzheimer’s disease.